| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TriSalus Life Sciences, Inc.$4.14
+0.25 (+6.43%)
D 36Pipeline Score MedTech · Clinical
Market Cap
200.22 M
EPS
-1.41
P/E Ratio
-
Value Trade
640.42 K
SEC Financials
Q1 2026Dilution Risk
Revenue
8.90 M
R&D Expenses
3.22 M
Operating CF
-6.48 M
Total Assets
70.98 M
Total Liabilities
58.17 M
Equity
12.81 M
D/E Ratio
12,345
31.45 %
Week
-27.56 %
1 Month
-33.6 %
3 Month
-32.08 %
6 Month
-66.9 %
5 Year
-70.36 %
All Time
Cash Data
Cash Position
56.55 M
Monthly Burn
2.16 M
Runway
24.5 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
234.85 K
52 Week Range
2.20 - 7.95
% held by Insiders
38.04 %
% held by Institutions
36.66 %
Enterprise Value
178.15 M
Total Shares
61.37 M
Short %
5.75 %
Float Shares
40.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for TriSalus Life Sciences, Inc.
102Total events
2Upcoming
18Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 2
Event history 100
Jun 24, 2026
◆Oral PresentationPresentation
Virtual KOL event featuring new real-world evidence for Pressure-Enabled Drug Delivery in liver cancer
liver cancersource ↗
May 12, 2026
▲PublicationPresentation
Real-world PEDD study published in Journal of Comparative Effectiveness Research
liver tumorssource ↗
May 4, 2026
▲Trial InitiationTrial
Launch of PREDICTT clinical trial evaluating Pressure-Enabled Drug Delivery in liver tumors
liver tumorssource ↗
Apr 14, 2026
◆Oral PresentationPresentation
Novel Approaches to Uterine Artery Embolization: A Clinical Assessment of Safety and Efficacy Using a Pressure Enabled Drug Delivery Device
Uterine fibroidssource ↗
Apr 13, 2026
◆Poster PresentationPresentation
Pressure Enabled Drug Delivery During Delivery of Embolic Spheres Enhances Hepatic Tumor Penetration in an Oncopig Model
Hepatic tumorssource ↗
Apr 13, 2026
◆Oral PresentationPresentation
Embolization of Neuroendocrine Tumor Metastases to the Liver: A Single-Center Experience Before and After the Introduction of Pressure Enabled Drug Delivery
Neuroendocrine tumor metastases to the liversource ↗
Apr 7, 2026
Feb 20, 2026
▼Equity OfferingCorporate
Pricing of $40.0 million public offering of 9,756,100 shares at $4.10 per share
Feb 19, 2026
Drug Pipeline Intelligence
D36
Pipeline Score $152M
Pipeline ValueValuation Signal
2
Drugs Scored0.8x
rNPV / MCap Top 49%
Micro Cap (rank 466 of 911)
Percentile RankTriSalus Life Sciences, Inc. faces pipeline headwinds (36/100), with $608M risk-adjusted pipeline value, led by Pembrolizumab in Prostatic Neoplasms (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab Small molecule | Prostatic Neoplasms | Phase 2 | NCT03007732 | 19% | $588M | COMPLETED | 23 | - | - | Mar 31, 2025 | - | Dec 5, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SD-101 | uveal melanoma liver metastases | Phase 1 | 2023-06-12 | treatment related serious adverse event rate: 5%; patients enrolled: 39; treatment naive patients: 5; patients failed prior therapy: 81%; stable disease patients: 15; partial response patients: 1; ct DNA decrease patients: 8; evaluable patients: 13 Read More | TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting New dat Read More | |
SD-101 | uveal melanoma liver metastases | Phase 1 | 2023-06-12 | treatment related serious adverse event rate: 5%; patients enrolled: 39; treatment naive patients: 5; patients failed prior therapy: 81%; stable disease patients: 15; partial response patients: 1; ct DNA decrease patients: 8; evaluable patients: 13 Read More | TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting New dat Read More | |
SD-101 | uveal melanoma liver metastases | Phase 1 | 2023-06-12 | treatment related serious adverse event rate: 5%; patients enrolled: 39; treatment naive patients: 5; patients failed prior therapy: 81%; stable disease patients: 15; partial response patients: 1; ct DNA decrease patients: 8; evaluable patients: 13 Read More | TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting New dat Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TLSI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TLSI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TLSI▲ +6.3%on this news· ran to +26% by day 3
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences is set to host a virtual Key Opinion Leader (KOL) event on June 24. The event will showcase new real-world evidence regarding their Pressure-Enabled Drug Delivery™ technology specifically for liver cancer treatment. This initiative highlights the company's commitment to advancing therapeutic options in oncology.
Read more →TLSIReal-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
The article discusses a real-world study published in the Journal of Comparative Effectiveness Research that highlights improved clinical outcomes and charge avoidance related to PEDD. However, specific details about the study's findings or implications are not provided in the text.
Read more →TLSITriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
TriSalus Life Sciences has reported its first quarter 2026 results, highlighting both commercial and clinical advancements aimed at fostering long-term growth. The report indicates the company's ongoing efforts to enhance its market position and clinical outcomes. However, specific details regarding financial performance or clinical data were not disclosed in the article.
Read more →TLSITriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
TriSalus Life Sciences has announced the launch of the PREDICTT clinical trial, which aims to evaluate a novel pressure-enabled drug delivery system for treating liver tumors. This innovative approach could enhance the effectiveness of therapies for patients with this challenging condition. The trial represents a significant step forward in cancer treatment methodologies.
Read more →TLSITriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences will host a conference call on May 12, 2026, to discuss its financial results for Q1 2026. The company focuses on integrating novel delivery technology with standard therapies for solid tumors. Their investigational immunotherapeutic, nelitolimod, aims to enhance treatment outcomes by addressing immunosuppressive environments. A press release will precede the call.
Read more →TLSITriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences will present new data at the Society of Interventional Radiology Annual Scientific Meeting in April 2026. The company will showcase its Pressure Enabled Drug Delivery platform, which aims to enhance therapeutic delivery for solid tumors. Presentations will include findings on hepatic tumor penetration and uterine artery embolization. The data supports the potential of PEDD in improving treatment outcomes.
Read more →TLSITriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
TriSalus Life Sciences has announced the appointment of Richard Marshall, M.D., as their new Chief Medical Officer. This strategic move is expected to enhance the company's leadership team. Further details regarding his previous experience and future plans at TriSalus were not disclosed in the announcement.
Read more →TLSITriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences will host a conference call on March 5, 2026, to discuss its financial results for Q4 2025. The call will provide insights into the company's performance and future plans, including its innovative drug delivery technologies and investigational immunotherapeutic, nelitolimod. A press release will precede the call, and a replay will be available afterward.
Read more →TLSI▲ +18.2%on this news
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
TriSalus Life Sciences has announced the pricing of its public offering, selling 9,756,100 shares at $4.10 each, aiming to raise approximately $40 million. The offering is expected to close around February 23, 2026, pending customary closing conditions. Lake Street Capital Markets is the sole book-runner for this offering.
Read more →TLSITriSalus Life Sciences Proposes Public Offering WESTMINSTER, Colo.-(BUSINESS WIRE)
TriSalus Life Sciences, an oncology-focused medical technology company, announced its intent to conduct an underwritten public offering of its common stock. The offering entails all shares being sold by the company, with underwriters receiving an option for additional shares. The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC. Various aspects of the public offering and TriSalus's future potential treatments are discussed in light of market conditions and regulatory compliance.
Read more →TLSITriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
TriSalus Life Sciences has appointed Michael Stansky to its Board of Directors, effective February 4, 2026, following the resignation of Dr. Arjun Desai. Stansky brings 40 years of experience in investment management and healthcare, which the company believes will support its strategic growth objectives. The board expressed gratitude for Desai's contributions during his tenure.
Read more →TLSITriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock WESTMINSTER, CO
TriSalus Life Sciences has successfully completed its exchange offer for Series A Convertible Preferred Stock, with nearly 99% of shares tendered in the process. The exchange allows holders to convert their preferred shares into common stock at a ratio of 3.3 shares. The SEC's effective declaration of the registration statement facilitates this transition, which is expected to be finalized by August 1, 2025. The initiative highlights the company's ongoing focus on oncology advancements and improving patient outcomes.
Read more →TLSI▼ -8.8%on this news
TriSalus Life Sciences Announces Chief Financial Officer Transition with Appointment of David B. Patience David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO
TriSalus Life Sciences has announced the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. He succeeds James E. Young, who stepped down for personal reasons. David Patience brings extensive experience from his previous role as CFO at Accelerate Diagnostics and has a strong background in strategic product planning and market analysis. The transition aims to maintain stability while leveraging Patience's financial leadership in the company's growth efforts.
Read more →TLSI▼ -10.3%on this news
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Ant
TriSalus Life Sciences has announced a private placement of $22 million, aimed at accelerating current and future applications of its cancer treatment technologies. Preliminary financial results for Q1 2025 indicate a revenue of approximately $9.2 million, reflecting a 42% growth compared to Q1 2024. The company plans to simplify its capital structure through an exchange offer for its Series A Convertible Preferred Stock, which is expected to enhance operational efficiency. The funds raised will be utilized for working capital and corporate purposes, as the company continues to advance its innovative therapies for solid tumors.
Read more →TLSI▼ -7.2%on this news
TriSalus Announces Leadership Changes James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Operations DENVER
TriSalus Life Sciences has announced key leadership changes effective January 6, 2025. James Young is the new Chief Financial Officer, succeeding Sean Murphy, who continues as Chief Manufacturing, Strategy, and Business Development Officer. Dr. Richard Marshak has been promoted to Chief Commercial Officer and Jodi Devlin to Chief of Clinical Operations. The company believes these changes reflect its growth momentum and readiness to achieve strategic goals for 2025.
Read more →TLSI▼ -10.9%on this news
TriSalus Reports Q3 2024 Financial Results and Provides Business Update Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year Provided 2025 guidance with expect
TriSalus Life Sciences (TLSI) reported its Q3 2024 financial results, showcasing a 42% increase in revenue, reaching $7.3 million. The company launched the TriNav LV Infusion System, targeting the embolization market with high expectations for future growth. Additionally, it presented positive Phase 1 trial results for its drug nelitolimod in patients with uveal melanoma. For 2025, TLSI anticipates over 50% revenue growth and aims to achieve positive cash flow in the latter half of the year.
Read more →TLSITriSalus Reports Q2 2024 Financial Results and Business Update Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended
TriSalus Life Sciences Inc. reported strong financial results for Q2 2024, highlighting $7.4 million in revenues, a 60% increase year-over-year. The company successfully advanced its nelitolimod clinical studies, treated 100 patients across multiple indications, and launched the DELIVER program to enhance treatment efficacy. Despite the revenue growth, TriSalus reported operating losses of $8.2 million, raising concerns regarding the sustainability of operations as they rely on achieving debt financing milestones. The company expects sufficient cash runway to fund operations through the end of 2025.
Read more →TLSITriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation WESTMINSTER, CO -- (BUSINESS WIRE)
TriSalus Life Sciences has completed its exchange offer and consent solicitation concerning its publicly traded warrants. The company issued over 2.1 million shares of common stock in exchange for these warrants. Additionally, the SEC has declared the company's registration statement effective, facilitating this capital transaction. This move is part of TriSalus's ongoing strategy to integrate its novel drug delivery technology with immunotherapy for treating liver and pancreatic tumors.
Read more →TLSITriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants WESTMINSTER, CO -- (BUSINESS WIRE)
TriSalus Life Sciences announced the expiration and results of its exchange offer and consent solicitation for its warrants. Approximately 78.89% of Public Warrants were successfully tendered in the offer, with the company expecting to accept these for settlement by July 1, 2024. The company's Registration Statement was declared effective on June 25, 2024, allowing for shares to be issued in this process. However, the warrant amendment for Private Placement Warrants and Working Capital Warrants did not receive the necessary approvals.
Read more →TLSI▼ -20.8%on this news
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants DENVER -- (BUSINESS WIRE)
TriSalus Life Sciences has initiated an exchange offer and consent solicitation concerning its warrants to streamline its capital structure. The initiative aims to mitigate the dilutive impact of the warrants by providing holders an opportunity to exchange them for shares of common stock. The company has already garnered support from a significant portion of Public Warrants holders, but the effectiveness of the proposal hinges on further consent from a majority. The offer will expire on June 25, 2024, or may be extended by the company.
Read more →TLSI▼ -7.5%on this news
TriSalus Reports Q1 2024 Financial Results and Business Update Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported Gross Margin of 85% in 1Q24 Secured up to $50 million of debt financing with Orb
TriSalus Life Sciences Inc. reported a substantial 116% revenue increase, reaching $6.5 million in Q1 2024 compared to the previous year. The company's gross margin also improved to 85%, highlighting effective operational scaling. They secured up to $50 million in debt financing to bolster the growth of their TriNav Infusion System. Despite these positive developments, TriSalus faces ongoing operating losses and a need for revenue thresholds to unlock further financing. The appointment of a new board member, Liselotte Hyveled, is expected to enhance their leadership team as they pursue their growth strategy.
Read more →TLSITriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives $25 million funded at close; up to $25 million of additional capital available at the C
TriSalus Life Sciences has completed a debt financing agreement with OrbiMed, securing up to $50 million to support its growth initiatives for the TriNav Infusion System. The initial $25 million has been funded, with an additional $25 million available upon meeting specific revenue criteria. This financing is designed to enhance the company's financial flexibility and aims to extend its cash runway through 2025, with expectations of reaching break-even EBITDA by that year. However, the company also faces risks related to clinical development and potential future capital needs.
Read more →TLSI▲ +5.1%on this news
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 9
TriSalus Life Sciences Inc. announced its Q4 and full year 2023 financial results, highlighting a 77% increase in Q4 revenue compared to the prior year and a total annual revenue growth of 49%. The company achieved notable milestones, including permanent reimbursement for its TriNav Infusion System. However, TriSalus also reported significant net losses for both the fourth quarter and the full year, along with the need to file for a late submission of its Annual Report due to identified errors in financial reporting. Plans for ongoing clinical trials and new product clearances indicate a strategic focus on future growth.
Read more →TLSITriSalus Life Sciences January 2024 2 Disclaimer Certain statements in this presentation may constitute "forward looking statements" within the meaning of applicable United S tat es federal securities laws. Forward looki
TriSalus Life Sciences has issued a presentation that includes forward-looking statements about its clinical strategies, product candidates, and financial expectations. The company emphasizes its innovative approach using a Pressure Enabled Drug Delivery (PEDD) system in conjunction with its product SD-101 to address critical barriers in treating liver and pancreatic tumors. Although there is potential for significant market growth, the company acknowledges various risks that could impact its future success, particularly the uncertainties surrounding clinical trial outcomes and market conditions.
Read more →TLSITriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 milli
TriSalus Life Sciences, now publicly trading under ticker TLSI, reported third-quarter 2023 revenues of $5.2 million, marking a 32% increase year-over-year. The company highlighted favorable clinical trial data for its innovative treatment technologies targeting liver and pancreatic tumors. Despite increased revenues and improved gross margins, TriSalus also reported significant operating losses of $18.5 million for the quarter. Looking ahead, the company is focused on advancing its clinical trials and expanding its commercialization efforts.
Read more →TLSISTANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this " Agreement ") dated as of
Trisalus Life Sciences, Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows the company to issue and sell up to $30 million in shares of its common stock. The arrangement reflects the confidence of the investor in the company's potential. The common shares will be issued in accordance with applicable securities regulations.
Read more →TLSI▼ -7.1%on this news· ran to -22% by day 3
OUR MISSION : TriSalus Life Sciences seeks to Transform the way liver and pancreatic tumors are treated through our immunotherapeutic and drug delivery technology TriSalus Life Sciences SEPTEMBER 2023 Disclaimer 2023 Tri
TriSalus Life Sciences aims to revolutionize treatment for liver and pancreatic tumors through its innovative immunotherapeutic and drug delivery technology. The company is focused on addressing areas with significant unmet medical need and has promising data from its lead therapy, SD-101, indicating well-tolerated safety and efficacy. With sales growth projected and key data readouts expected through 2024, TriSalus is positioned for value creation in both niche and large markets. Their proprietary Pressure Enabled Drug Delivery technology is also anticipated to enhance therapeutic penetration in challenging tumor environments.
Read more →TLSITRISALUS LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands except share and per share data)
TriSalus Life Sciences, Inc. released its condensed consolidated balance sheets for June 30, 2023, revealing a decline in total assets and an increase in accumulated deficits. The company's revenue has grown, but it still reported a significant net loss. While there were positive aspects such as improved cash collection and an increase in additional paid-in capital, overall financial health appears to be deteriorating, with net losses increasing compared to the previous year.
Read more →TLSIMedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
MedTech Acquisition Corporation has adjourned its special meeting of stockholders, which was intended to discuss the proposed business combination with TriSalus Life Sciences. The meeting is now rescheduled for August 8, 2023, allowing stockholders more time to consider their positions. In preparation for the meeting, MedTech filed a report regarding TriSalus' communications with the FDA concerning its clinical program. This delay raises concerns about the potential impact on stockholder sentiment and the future of the business combination.
Read more →TLSITriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting New dat
TriSalus Life Sciences announced positive results from its Phase 1 PERIO-01 clinical trial for SD-101 in uveal melanoma liver metastases at ASCO 2023. The study demonstrated a low treatment-related serious adverse event rate and significant immunological responses, including natural killer cell expansion and decreased levels of circulating tumor DNA. The findings support SD-101's potential role in improving treatment outcomes for patients with this aggressive cancer type. TriSalus plans to advance to Phase 2 trials based on these encouraging results.
Read more →TLSITriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases DENVER and
TriSalus Life Sciences presented new Phase 1 clinical data on its investigational drug SD-101 at the AACR 2023 Annual Meeting. The study focused on patients with stage IV uveal melanoma and liver metastases, utilizing the Pressure-Enabled Regional Immuno-Oncology method for drug delivery. Initial results suggest that SD-101 is well tolerated with few serious adverse effects, and patients exhibited encouraging reductions in circulating tumor DNA levels. TriSalus remains optimistic about the potential of its delivery method to enhance the efficacy of immunotherapies.
Read more →TLSITriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business DENVER and CHICAGO
TriSalus Life Sciences has appointed James Alecxih as President of the Device Technology Business, a critical role for overseeing the TriNav Infusion System's growth. Alecxih brings over 30 years of experience in medical device product development and commercialization. This leadership change comes as TriSalus is preparing to go public through a merger with MedTech Acquisition Corporation, anticipated to finalize in the second quarter of 2023, subject to regulatory approval. The TriNav system aims to enhance therapeutic delivery for patients with liver and pancreatic cancers within a unique platform approach that integrates immunotherapy.
Read more →TLSITriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology -01 and -02 Studies Data Further Support
TriSalus Life Sciences has released updated data from its Phase 1 and 1b clinical trials for SD-101, which is administered via the Pressure-Enabled Drug Delivery (PEDD) system. The data indicates that this investigational drug may improve treatment outcomes for patients with liver and pancreatic tumors, particularly uveal melanoma. As of February 2023, 42 patients are enrolled in the trials, with positive early findings suggesting the potential of SD-101 in conjunction with checkpoint inhibitors. TriSalus plans to provide additional data and expand clinical trials in the latter half of 2023.
Read more →TLSITriSalus Video Transcript Text on screen: Dr. Carvajal is a Member of the TriSalus Scientific Advisory Board and Investigator for the PERIO-01 Study. My name is Rich Carvajal. I'm a medical Oncologist at Columbia Univers
TriSalus Video Transcript Text on screen: Dr. Carvajal is a Member of the TriSalus Scientific Advisory Board and Investigator for the PERIO-01 Study. My name is Rich Carvajal. I'm a medical Oncologist at Columbia University Irving Medical Center where I oversee the melanoma p
Read more →TLSITriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology (PERIO ) Clinical Trial Progress and Pre-clinical Research Developments DENVER and CHICAGO
TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology (PERIO ) Clinical Trial Progress and Pre-clinical Research Developments DENVER and CHICAGO, December 15, 2022 - TriSalus Life Sciences , Inc. ("TriSalus" or the "company"), an oncology company in the p
Read more →TLSITriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology (PERIO ) 01 and 02 Clinical Studies DENVER and CHICAGO
TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology (PERIO ) 01 and 02 Clinical Studies and CHICAGO, November 21, 2022 - TriSalus Life Sciences , Inc. ("TriSalus") (the "Company"), an oncology therapeutics company in the process of going public
Read more →TLSIList of Participants Chris Dewey, Chief Executive Officer, MedTech Acquisition Corporation Mary Szela, Chief Executive Officer, TriSalus Steven Katz, Chief Medical Officer, TriSalus Sean Murphy, Chief Financial Officer,
List of Participants Hello, and welcome to today's conference call to discuss the merger between TriSalus Life Sciences and MedTech Acquisition Corp. At this time, all participants are in listen-only mode. There will be no questions and answer session following the formal pre
Read more →TLSITriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disrup
Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology Company Has a Differentiated and Fast-growin
Read more →TLSIMedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination Tel Aviv, Israel and Fort Lauderdale, FL
MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination Tel Aviv, Israel and Fort Lauderdale, FL, March 10, 2022 -MedTech Acquisition Corporation (Nasdaq: MTAC) ("MedTech"), a publicly traded special purpose acquisitio
Read more →TLSIMemic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination Memic's Hominis platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shape
Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination Tel Aviv, Israel and Fort Lauderdale, FL, August 13, 2021 - Memic Innovative Surgery Ltd. (the "Company" or "Memic"), a medical device company dedicated to transforming su
Read more →TLSIMedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q New York, NY
MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q New York, NY, June 2, 2021 (GLOBE NEWSWIRE) - MedTech Acquisition Corporation (Nasdaq: MTACU) (the "Company") today announced that it has received a
Read more →TLSIMedTech Acquisition Corporation Announces Separate Trading of its Class A Common Stock and Warrants, Commencing
Corporation Announces Separate Trading of its Class A Common Stock and Warrants, Commencing February 8, 2021 New York, NY, February 5, 2021 /PRNewswire/ - MedTech Acquisition Corporation (Nasdaq:MTACU) (the "Company") announced today that, commencing February 8, 2021, holders
Read more →TLSIMEDTECH ACQUISITION CORPORATION INDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of MedTech Acquisition Corporation: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
MEDTECH ACQUISITION CORPORATION INDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of MedTech Acquisition Corporation: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of December 22, 2020 F-3 Notes to Financial Statement F-4 REPOR
Read more →TLSIMedTech Acquisition Corporation Announces Pricing of Upsized $220,000,000 Initial Public Offering New York, NY
MedTech Acquisition Corporation Announces Pricing of Upsized $220,000,000 Initial Public Offering New York, NY, December 17, 2020 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (the "Company") announced today that it priced its upsized initial public offering of 22,000,0
Read more →Competitive Position
How TLSI ranks across every disease it competes inCompetitive Position is a premium feature
See how TLSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial